Chimeric Therapeutics Limited (ASX:CHM)

26.5¢

right-arrow Created with Sketch. 0.005 (1.92%)
MCAP $86.69M
Last trade 13.07pm 06/12/2021 20mins delayed

Latest Announcements

03/12/2021CHMChimeric Therapeutics Limited
03/12/2021CHMChimeric Therapeutics Limited
01/12/2021 Price SensitivePSCHMChimeric Therapeutics Limited
01/12/2021 Price SensitivePSCHMChimeric Therapeutics Limited
22/11/2021CHMChimeric Therapeutics Limited
22/11/2021CHMChimeric Therapeutics Limited
342
MCap
22/11/2021 Price SensitivePSCHMChimeric Therapeutics Limited
15/11/2021 Price SensitivePSCHMChimeric Therapeutics Limited

Company Overview

Chimeric Therapeutics Limited is an Australia-based company engaged in developing CAR T cell therapies for solid tumors. The Company's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.

CHM in the news

Chimeric Therapeutics (CHM) releases two CLTX CAR T abstracts showing positive results…
Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical…
Chimeric Therapeutics (CHM) enters a strategic partnership with Oncobay Clinical to advance…
Chimeric Therapeutics’ (CHM) Chief Operating Officer takes the reins as Chief Executive…

Search Previous Announcements